Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 264
Selected: 0
NCT IDTitle
NCT07118800Study Evaluating Two Treatment Strategies for Rectal Cancer in Patients ≥75 Years Old
NCT00423696Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
NCT03667417Genetic Predisposition to Breast and Ovarian Cancer: Prospective Study of BRCAx Gene Mutation
NCT07259226Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers
NCT04595565Sacituzumab Govitecan in Primary HER2-negative Breast Cancer
NCT00003606Combination Chemotherapy in Treating Patients With Extensive Stage Small Cell Lung Cancer
NCT02754011Phase I Evaluating the Combination of Ribociclib+Capecitabine in Locally Advanced/Metastatic Breast Cancer HER2 Negative
NCT03946033Impact of Immunoscore Colon Test on Adjuvant Therapeutic Strategy in Non-Metastatic Colon Cancer
NCT03838263Feasibility and Tolerance of Nivolumab Neoadjuvant Immunotherapy in High Risk HPV Driven Oropharynx Cancer
NCT01993498Chronic Toxicities Related to Treatment in Patients With Localized Cancer
NCT03532204Oligometastases of the LIVer Treated With Chemotherapy With ou Without Extracranial Stereotactic Body Radiation Therapy in Patients With Colorectal Cancer
NCT02701907EXPRESS: EXcePtional RESponSe - Exceptional and Unexpected Response to Targeted Therapies
NCT04115007Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients
NCT04053322Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.
NCT00424203Doxorubicin and Cyclophosphamide in Treating Older Women With Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery
NCT07193394Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer
NCT01526135Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus mFolfirinox to Treat Resected Pancreatic Adenocarcinoma
NCT03132038Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck
NCT06446882Diagnostic HER2DX-guided Treatment for Patients wIth Early-stage HER2-positive Breast Cancer
NCT03101046Treatment of Metastatic Castrate Resistant Prostate Cancer Patients According to Circulating Tumor Cells Kinetic
NCT00002883Surgery With or Without Combination Chemotherapy in Treating Patients With Cancer of the Esophagus
NCT02947685Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
NCT05296746Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer
NCT03848052Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 (ESME LC)
NCT00423475Radiation Therapy With or Without Goserelin in Treating Patients Who Have Undergone Surgery for Recurrent or Refractory Prostate Cancer
NCT01564056Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment
NCT02215265Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS)
NCT03275311Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008
NCT04985266A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer
NCT00103168Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor
NCT05297617Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk
NCT03079011PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection
NCT01443065MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma
NCT00006119Hydroxyurea in Treating Patients With Recurrent and/or Unresectable Meningioma
NCT04450836Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer
NCT01620242A Phase II, Open-Label, Multicenter Trial of Cabazitaxel in Patients With Recurrent or Metastatic Head and Neck Cancer After Failure Of Cisplatin, Cetuximab and Taxanes
NCT03722108Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas
NCT01805271Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy
NCT03012620Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types
NCT02818725I-MVAC +/- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras Mutations
NCT05947903Validation of the European Oncology Quality of Life Toolkit
NCT06505018Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment
NCT02843386Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma
NCT00003654Diagnostic Study to Identify Sentinel Lymph Nodes in Women With Stage I or Stage II Breast Cancer
NCT00003860Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Small Cell Lung Cancer
NCT03077776Tracking Triple-negative Breast Cancer Evolution Through Therapy
NCT00083174Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
NCT03386162SAFIR-PI3K A Phase II Randomized Maintenance Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy in PIK3CA Mutated Advanced Breast Cancer
NCT06529718Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients
NCT02822482Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss